GH Research PLC Asset Resilience Ratio
GH Research PLC asset resilience ratio. GH Research PLC (GHRS) has an Asset Resilience Ratio of 4.73% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GHRS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of GH Research PLC (2022–2025)
Asset resilience ratio of GH Research PLC from 2022 to 2025. This chart shows how GH Research PLC's Asset Resilience Ratio has changed over time. Read debt load of GH Research PLC for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down GH Research PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GH Research PLC asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $17.60 Million | 4.73% |
| Total Liquid Assets | $17.60 Million | 4.73% |
Asset Resilience Insights
- Limited Liquidity: GH Research PLC maintains only 4.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GH Research PLC Industry Peers by Asset Resilience Ratio
Compare GH Research PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
GH Research PLC Asset Resilience Ratio by Year (2022–2025)
GH Research PLC asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for GH Research PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 11.95% | $34.46 Million | $288.23 Million | -13.82pp |
| 2024-12-31 | 25.78% | $48.53 Million | $188.27 Million | -10.96pp |
| 2023-12-31 | 36.74% | $83.14 Million | $226.30 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $254.36 Million | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II… Read more